Posted On: 02/14/2015 11:48:41 AM
Post# of 30066
In a private message I asked Chris for a little help on what CRAO was. Thanks for the reply Chris.
Here's a little of what I found...
In October 2014, animal data on the use of MANF in ocular disorders was presented by Roman Urfer, PhD, at the Targeting Ocular Disorders (TOD) conference in Boston, MA. The presentation, "MANF - A Novel Neurotrophic Factor for the Treatment of Retinal Disorders," demonstrated that MANF provided positive protective functional effects in animal models of central retinal vein occlusion (CRVO), as well as central retinal artery occlusion (CRAO) and glaucoma.
Same article...
The market exclusivity and strong pricing power conferred by the granting of a U.S. FDA Orphan Drug Destination make things attractive from a partnering standpoint. Companies that are marketing drugs targeting ocular diseases include Regeneron, Novartis/Alcon, Pfizer, Roche, and Bayer. We expect the U.S. FDA to respond to Amarantus ODD application in early 2015.
Here's a little of what I found...
In October 2014, animal data on the use of MANF in ocular disorders was presented by Roman Urfer, PhD, at the Targeting Ocular Disorders (TOD) conference in Boston, MA. The presentation, "MANF - A Novel Neurotrophic Factor for the Treatment of Retinal Disorders," demonstrated that MANF provided positive protective functional effects in animal models of central retinal vein occlusion (CRVO), as well as central retinal artery occlusion (CRAO) and glaucoma.
Same article...
The market exclusivity and strong pricing power conferred by the granting of a U.S. FDA Orphan Drug Destination make things attractive from a partnering standpoint. Companies that are marketing drugs targeting ocular diseases include Regeneron, Novartis/Alcon, Pfizer, Roche, and Bayer. We expect the U.S. FDA to respond to Amarantus ODD application in early 2015.
(0)
(0)
